Covaxin shows 100% efficacy against 'severe Covid-19', 78% overall

The Bharat Biotech candidate has also shown 70 per cent efficacy against asymptomatic infections, suggesting that it prevents transmission

Bharat Biotech’s Covaxin has shown an overall efficacy of 78 per cent against Covid-19 and 100 per cent efficacy against a severe form of the disease, the vaccine maker said on Wednesday.
 
The vaccine has also shown 70 per cent efficacy against asymptomatic infections, suggesting that it prevents transmission. The second interim analysis of Covaxin’s Phase 3 clinical trials is based on accruing 87 symptomatic cases of the virus.
 
Trials are double-blinded and the investigator and volunteer do not know if they have received a placebo or a vaccine shot. After a certain statistical number of cases of